Jan 16, 2020 / 05:00PM GMT
Yuko Oku - JP Morgan Chase & Co, Research Division - Analyst
Hi. I'm Yuko Oku, one of the associates on the biotech team. It's a pleasure to introduce Mersana to the JPMorgan Healthcare Conference today. Just a quick housekeeping note, we'll be hosting a Q&A session right after the presentation in the Victorian Room. And with that, I'd like to turn it over to President and CEO, Anna Protopapas.
Anna Protopapas - Mersana Therapeutics, Inc. - President, CEO & Director
Thank you. Before I start, I just want to remind you that I will be making forward-looking statements. 2020 is a very important year for Mersana. It's a year rich in both milestones and data disclosures. Our lead asset, 1536, is a first-in-class molecule addressing important unmet medical needs in ovarian and lung adenocarcinoma. 1536 is in 2 proof-of-concept studies that are on track to complete in 2020 and then subsequently support registration-enabling studies, including fast-to-market opportunities in later-stage ovarian cancer patients.
Beyond 1536, we have a new IND and 2
Mersana Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers